Cargando…

Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?

In 2020, ASCO recommended that all women with epithelial ovarian cancer have germline testing for BRCA1/2 mutations, and those without a germline pathogenic variant (PV) should have somatic tumor testing to determine eligibility for a poly (ADP-ribose) polymerase inhibitor. Consequently, the majorit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Janice S., Tinker, Anna V., Santos, Jennifer, Compton, Katie, Sun, Sophie, Schrader, Kasmintan A., Karsan, Aly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616645/ https://www.ncbi.nlm.nih.gov/pubmed/36265114 http://dx.doi.org/10.1200/PO.22.00033

Ejemplares similares

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention
por: Hanley, Gillian E., et al.
Publicado: (2018)

Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing
por: Vlessis, Katherine, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
por: Jang, Jaehyeok, et al.
Publicado: (2023)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
por: Peixoto, Ana, et al.
Publicado: (2020)

BRCA germline mutation test for all woman with ovarian cancer?
por: Paradiso, A. V., et al.
Publicado: (2019)

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
por: Cham, Stephanie, et al.
Publicado: (2022)

Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System
por: Richardson, Matthew, et al.
Publicado: (2020)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?
por: Nguyen-Dumont, Tu, et al.
Publicado: (2020)

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
por: Eccleston, Anthony, et al.
Publicado: (2017)

Somatic TP53 variants frequently confound germline testing results
por: Weitzel, Jeffrey N., et al.
Publicado: (2017)

The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high‐grade serous ovarian cancer: a national retrospective audit
por: Frugtniet, B, et al.
Publicado: (2021)

Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study
por: Chandrasekaran, Dhivya, et al.
Publicado: (2021)

Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2
por: Barbosa, Ana, et al.
Publicado: (2020)

Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome
por: Yoshihama, Tomoko, et al.
Publicado: (2020)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
por: Sahnane, Nora, et al.
Publicado: (2020)

Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
por: Akaev, Iolia, et al.
Publicado: (2021)

Prevalence of pathogenic germline variants in the circulating tumor DNA testing
por: Yamamoto, Yoshihiro, et al.
Publicado: (2022)

Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria
por: Andoni, Tala, et al.
Publicado: (2022)

An improved burden-test pipeline for identifying associations from rare germline and somatic variants
por: Geng, Yu, et al.
Publicado: (2017)

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing
por: Mafficini, Andrea, et al.
Publicado: (2016)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
por: Golan, Talia, et al.
Publicado: (2023)

Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice
por: Meiser, Bettina, et al.
Publicado: (2021)

Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma
por: Azzollini, Jacopo, et al.
Publicado: (2023)

UK BRCA mutation testing in patients with ovarian cancer
por: George, Angela
Publicado: (2015)

Cost-effective BRCA Testing in Advanced Ovarian Cancer
por: Kim, Myungshin
Publicado: (2023)

Identification of germline cancer predisposition variants in pediatric sarcoma patients from somatic tumor testing
por: Alba-Pavón, Piedad, et al.
Publicado: (2023)

New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
por: Plaskocinska, Inga, et al.
Publicado: (2016)

Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer
por: Kanchi, Krishna L., et al.
Publicado: (2014)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer
por: Chao, Angel, et al.
Publicado: (2016)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing
por: Patruno, Margherita, et al.
Publicado: (2021)

Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
por: Hong, Joohyun, et al.
Publicado: (2021)

Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing
por: Stegel, Vida, et al.
Publicado: (2022)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication
por: Pollard, Samantha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_snd2tqq5rpe0bh9bd0vjqmqmbc